Navigation Links
BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
Date:11/5/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Rodman and Renshaw 10th Annual Healthcare Conference in New York.

WHEN: Monday November 10th at 12:00pm (Eastern Time)

WHERE: New York Palace Hotel, New York.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, th
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
2. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
3. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
4. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
5. BioMS Medical to present at UBS Global Life Sciences Conference
6. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
7. BioMS Medical announces its intention to renew a normal course issuer bid
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. BioMS Medical Announces Second Quarter 2008 Results
10. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
11. BioMS Medical to present at BMO Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 3, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... are for odour control projects in North America ... Asia . "Bidding activity in 2015 continues to ... "After a high volume year for bidding in 2014, we are ... The recent orders reflect the organization,s renewed focus on select market ...
(Date:3/3/2015)... , March 3, 2015 Adaptive Biotechnologies ... CFO, is joining its Board of Director as Chair ... officer at Zillow Group, Chad oversees all finance, treasury ... built the company,s core finance, treasury and accounting functions, ... and nine acquisitions. In 2013, he was named Puget ...
(Date:3/3/2015)... March 3, 2015 Fried, Frank, Harris, Shriver ... Lewis has joined the Firm as a partner ... New York office. Mr. Lewis ... as well as other intellectual property and general litigation. ... Lewis represents both plaintiffs and defendants in a range ...
(Date:3/3/2015)... N.J. , March 3, 2015  Thingee Corporation, ... will be delivering a presentation entitled, "Technology Adoption: Making ... Thriving through Innovations and Technology ,  in ... March 11 to 13, 2015. Audiences looking to learn ... effectively will want to be in the audience for ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Thingee to present at 11th Annual Synergistix Users Conference 2
... BOSTON, Jan. 10, 2011 Entrega, Inc., a ... announced its formation by Enlight Biosciences, a Boston-based ... leading global pharmaceutical companies. As part of its ... spatially-directed proprietary drug delivery platform to create orally ...
... win. The professor of biotechnology at Delft University of ... in Rice University,s Matteo Pasquali. Together with ... (CNRS), the University of Bordeaux, France, and Vrije University, ... a long-standing controversy in the field of polymer dynamics: ...
... The Pittsburgh Life Sciences Greenhouse (PLSG), the organization ... growth programs to the region,s life sciences enterprises, issued ... John W. Manzetti announcing the first close of the ... Fund) at $5 million. The Accelerator Fund ...
Cached Biology Technology:New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma 2New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma 3Bendy tubes get around 2Bendy tubes get around 3Pittsburgh Life Sciences Greenhouse Announces the First Close of the PLSG Accelerator Fund LLC at $5 Million 2
(Date:2/5/2015)... 2015 Research and Markets ( ... "Global Biometrics Market (2014-2020): Market Forecast By ... report to their offering. , ... is anticipated to overtake North ... government spending towards IT security, government biometric based ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the ... report to their offering. , The ... individual is who she/he is claiming to be, and for ... unique physical characteristics, such as fingerprint, hand or palm print, ...
(Date:1/22/2015)... 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), the ... campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz will ... capacity to meet customer demand. Logo ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by Dr. ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... PASADENA, Calif.The frontal lobes are the largest part of ... that expanded most during human evolution. Damage to the ... eyescan result in profound impairments in higher-level reasoning and ... parts of the frontal lobes do, neuroscientists at the ...
... London and the University of Exeter Medical School has identified ... responsible for controlling eye muscles, resulting in movement disorders such ... could provide the key to reversing the condition and unlocking ... body. The research is published in Proceedings of ...
... Life in the world,s oceans faces far greater change and ... human history, a team of the world,s leading marine scientists ... Germany, Panama, Norway and the UK have compared events which ... what is observed to be taking place in the seas ...
Cached Biology News:Thinking and choosing in the brain 2Thinking and choosing in the brain 3Research identifies mechanism responsible for eye movement disorder 2Research identifies mechanism responsible for eye movement disorder 3Sea life 'facing major shock' 2Sea life 'facing major shock' 3
PGC-1 (H-300)...
Mouse VEGF R1/Flt-1 Phycoerythrin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Affinity Purified Anti-Human NP-1...
Biology Products: